13 June 2023: Original Paper
Incidence of Thromboembolic Complications Following Kidney Transplantation with Short and Extended Aspirin Prophylaxis: A Retrospective Single-Center Study
Angus H. Pegle 1ABCDEF* , Katharine Hegerty 1ACDE , Ryan P. Gately 12ACDE , Carmel M. Hawley 12AE , David W. Johnson 123ADE , Yeoungjee Cho 12AE , Dev K. Jegatheesan 12AE , Andrew B. McCann 4AE , Michelle E. Harfield 15AE , Nicole M. Isbel 123ACDEFDOI: 10.12659/AOT.939143
Ann Transplant 2023; 28:e939143
Table 1 Baseline characteristics and outcomes 6 weeks post-transplant stratified by 5-day and >6-week aspirin protocol.
| Characteristic | Overalln=1,2081 | 5 day protocoln=5711 | >6 week protocoln=6371 | p-value2 |
|---|---|---|---|---|
| 52.0 (41.0, 62.0) | 52.0 (40.0, 62.0) | 52.0 (42.0, 62.0) | 0.4 | |
| 0.2 | ||||
| Female | 446 (36.9%) | 201 (35.2%) | 245 (38.5%) | |
| Male | 762 (63.1%) | 370 (64.8%) | 392 (61.5%) | |
| c | 98 (13.1%) | 40 (10.3%) | 58 (16.2%) | |
| c | 32 (4.3%) | 18 (4.6%) | 14 (3.9%) | 0.7 |
| c | 23 (3.1%) | 13 (3.3%) | 10 (2.8%) | 0.7 |
| c | 642 (81.6%) | 330 (79.5%) | 312 (83.9%) | 0.12 |
| c | 226 (28.2%) | 103 (25.7%) | 123 (30.8%) | 0.11 |
| c | 51 (6.8%) | 28 (7.1%) | 23 (6.4%) | 0.7 |
| c | 0.076 | |||
| Current/Ex | 546 (49.2%) | 274 (52.0%) | 272 (46.7%) | |
| Never | 564 (50.8%) | 253 (48.0%) | 311 (53.3%) | |
| Anatomical | 156 (12.9%) | 74 (13.0%) | 82 (12.9%) | |
| Diabetic | 140 (11.6%) | 52 (9.1%) | 88 (13.8%) | |
| GN | 407 (33.7%) | 193 (33.8%) | 214 (33.6%) | |
| Polycystic | 199 (16.5%) | 113 (19.8%) | 86 (13.5%) | |
| Vascular | 82 (6.8%) | 39 (6.8%) | 43 (6.8%) | |
| Other | 224 (18.5%) | 100 (17.5%) | 124 (19.5%) | |
| 655.5 (322.5, 1,151.0) | 625.0 (316.0, 1,112.5) | 686.0 (323.0, 1,175.0) | 0.3 | |
| b | 0.4 | |||
| Haemodialysis | 618 (53.0%) | 280 (51.0%) | 338 (54.8%) | |
| Peritoneal dialysis | 480 (41.2%) | 238 (43.4%) | 242 (39.2%) | |
| Not on dialysis | 68 (5.8%) | 31 (5.6%) | 37 (6.0%) | |
| 0.4 | ||||
| First | 1,062 (87.9%) | 497 (87.0%) | 565 (88.7%) | |
| Previous | 146 (12.1%) | 74 (13.0%) | 72 (11.3%) | |
| 0.4 | ||||
| Cadaveric | 1,025 (84.9%) | 479 (83.9%) | 546 (85.7%) | |
| Live | 183 (15.1%) | 92 (16.1%) | 91 (14.3%) | |
| b | 47.0 (33.0, 56.0) | 46.0 (30.0, 57.0) | 47.0 (34.0, 55.5) | 0.3 |
| a | 0.3 | |||
| 0 | 49 (4.1%) | 20 (3.5%) | 29 (4.6%) | |
| 1 | 86 (7.1%) | 31 (5.5%) | 55 (8.7%) | |
| 2 | 259 (21.5%) | 123 (21.7%) | 136 (21.4%) | |
| 3 | 130 (10.8%) | 69 (12.1%) | 61 (9.6%) | |
| 4 | 230 (19.1%) | 111 (19.5%) | 119 (18.7%) | |
| 5 | 269 (22.4%) | 130 (22.9%) | 139 (21.9%) | |
| 6 | 180 (15.0%) | 84 (14.8%) | 96 (15.1%) | |
| 26 (2.2%) | 12 (2.1%) | 14 (2.2%) | >0.9 | |
| a | >0.9 | |||
| Single | 848 (70.7%) | 400 (70.7%) | 448 (70.7%) | |
| Multiple | 352 (29.3%) | 166 (29.3%) | 186 (29.3%) | |
| a | 0.6 | |||
| Single | 1,110 (92.7%) | 525 (93.1%) | 585 (92.3%) | |
| Multiple | 88 (7.3%) | 39 (6.9%) | 49 (7.7%) | |
| a | 3.1 (2.7, 3.7) | 3.1 (2.6, 3.6) | 3.2 (2.8, 3.8) | |
| 8.8 (5.9, 12.7) | 9.2 (6.1, 12.9) | 8.6 (5.7, 12.4) | 0.3 | |
| 0.5 (0.4, 0.6) | 0.5 (0.4, 0.6) | 0.5 (0.4, 0.6) | 0.4 | |
| b | 657 (56.9%) | 482 (84.7%) | 175 (29.9%) | |
| b | 0.088 | |||
| Steroid, mycophenolate, tacrolimus | 1,144 (95.7%) | 543 (96.8%) | 601 (94.8%) | |
| Other | 51 (4.3%) | 18 (3.2%) | 33 (5.2%) | |
| 62 (5.1%) | 35 (6.1%) | 27 (4.2%) | 0.14 | |
| 14 (1.2%) | 6 (1.1%) | 8 (1.3%) | 0.7 | |
| 36 (3.0%) | 27 (4.7%) | 9 (1.4%) | ||
| b | 7.0 (7.0, 9.0) | 7.0 (7.0, 9.0) | 7.0 (6.2, 9.0) | |
| 16 (1.3%) | 8 (1.4%) | 8 (1.3%) | 0.8 | |
| 1 (0.1%) | 0 (0.0%) | 1 (0.2%) | >0.9 | |
| 2 (0.2%) | 0 (0.0%) | 2 (0.3%) | 0.5 | |
| 17 (1.4%) | 8 (1.4%) | 9 (1.4%) | >0.9 | |
| 1 (0.1%) | 1 (0.2%) | 0 (0.0%) | 0.5 | |
| 103 (8.5%) | 50 (8.8%) | 53 (8.3%) | 0.8 | |
| b | 127.0 (101.0, 162.2) | 127.0 (102.0, 165.0) | 127.0 (100.0, 160.0) | 0.7 |
| 128 (10.6%) | 55 (9.6%) | 73 (11.5%) | 0.3 | |
| 16 (1.3%) | 8 (1.4%) | 8 (1.3%) | 0.8 | |
| 186 (15.4%) | 80 (14.0%) | 106 (16.6%) | 0.2 | |
| 1 (0.1%) | 0 (0.0%) | 1 (0.2%) | >0.9 | |
| 1 Median (IQR); n (%); 2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test. a b 1–5% missing data, c >5% missing data. CKD – chronic kidney disease; GN – glomerulonephritis; HLA – human leukocyte antigen; IVIG – intravenous immunoglobulin; VTE – venous thromboembolism. | ||||